Physician profile
Tejas Mehta
NPI 1225213804
$1,686.01
in general payments reported to CMS, 2019-2025
13 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $16.16 · 2021: $282 · 2022: $128 · 2023: $351 · 2024: $161 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $806.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $323.11 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $300.43 | 2019-2025 | Gattex, Eohilia |
| Abbvie INC. | $282.64 | 2019-2021 | |
| Qol Medical, LLC | $202.73 | 2019-2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $197.38 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $140.65 | 2019-2021 | |
| Janssen Biotech, INC. | $84.84 | 2019-2025 | Tremfya |
| Mirum Pharmaceuticals, INC. | $39.95 | 2023-2024 | Livmarli |
| Nestle Healthcare Nutrition INC. | $35.61 | 2022 | |
| Albireo Pharma, INC. | $28.18 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.09 | 2019 | |
| Pentax of America, INC. | $16.03 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejas Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.